Thesis (M. Med. Sc.)--University of Hong Kong, 2001. / Includes bibliographical references (leaves 26-32).

Thesis (Ph. D.)--University of Texas at Austin, 2001. / Vita. Includes bibliographical references. Available also from UMI/Dissertation Abstracts International.

Thesis (M.S.)--Brigham Young University. Dept. of Chemistry and Biochemistry, 2008. / Includes bibliographical references (p. 71-76).

Title from PDF of title page (University of Missouri--Columbia, viewed on March 10, 2010). The entire thesis text is included in the research.pdf file; the official abstract appears in the short.pdf file; a non-technical public abstract appears in the public.pdf file. Thesis advisor: Dr. Jianlin Cheng. Includes bibliographical references.

Thesis (Ph. D.)--University of Washington, 2002. / Vita. Includes bibliographical references (leaves 118-126).

published_or_final_version / Microbiology / Master / Master of Medical Sciences

published_or_final_version / Medical Sciences / Master / Master of Medical Sciences

A new generation of non-Sanger-based sequencing technologies, so called “next-generation” sequencing (NGS), has been changing the landscape of genetics at unprecedented speed. In particular, our capacity in deciphering the genotypes underlying phenotypes, such as diseases, has never been greater. However, before fully applying NGS in medical genetics, researchers have to bridge the widening gap between the generation of massively parallel sequencing output and the capacity to analyze the resulting data. In addition, even a list of candidate genes with potential causal variants can be obtained from an effective NGS analysis, to pinpoint disease genes from the long list remains a challenge. The issue becomes especially difficult when the molecular basis of the disease is not fully elucidated. New NGS users are always bewildered by a plethora of options in mapping, assembly, variant calling and filtering programs and may have no idea about how to compare these tools and choose the “right” ones. To get an overview of various bioinformatics attempts in mapping and assembly, a series of performance evaluation work was conducted by using both real and simulated NGS short reads. For NGS variant detection, the performances of two most widely used toolkits were assessed, namely, SAM tools and GATK. Based on the results of systematic evaluation, a NGS data processing and analysis pipeline was constructed. And this pipeline was proved a success with the identification of a mutation (a frameshift deletion on Hnrnpa1, p.Leu181Valfs*6) related to congenital heart defect (CHD) in procollagen type IIA deficient mice. In order to prioritize risk genes for diseases, especially those with limited prior knowledge, a network-based gene prioritization model was constructed. It consists of two parts: network analysis on known disease genes (seed-based network strategy)and network analysis on differential expression (DE-based network strategy). Case studies of various complex diseases/traits demonstrated that the DE-based network strategy can greatly outperform traditional gene expression analysis in predicting disease-causing genes. A series of simulation work indicated that the DE-based strategy is especially meaningful to diseases with limited prior knowledge, and the model’s performance can be further advanced by integrating with seed-based network strategy. Moreover, a successful application of the network-based gene prioritization model in influenza host genetic study further demonstrated the capacity of the model in identifying promising candidates and mining of new risk genes and pathways not biased toward our current knowledge. In conclusion, an efficient NGS analysis framework from the steps of quality control and variant detection, to those of result analysis and gene prioritization has been constructed for medical genetics. The novelty in this framework is an encouraging attempt to prioritize risk genes for not well-characterized diseases by network analysis on known disease genes and differential expression data. The successful applications in detecting genetic factors associated with CHD and influenza host resistance demonstrated the efficacy of this framework. And this may further stimulate more applications of high throughput genomic data in dissecting the genetic components of human disorders in the near future. / published_or_final_version / Biochemistry / Doctoral / Doctor of Philosophy

published_or_final_version / Medical Sciences / Master / Master of Medical Sciences

published_or_final_version / Medical Sciences / Master / Master of Medical Sciences